Publications by authors named "Lucas Lopez-Valero"
Introduction And Purpose: Atrial fibrillation (AF) is common in patients admitted with severe COVID-19. However, there is limited data about the management of chronic anticoagulation therapy in these patients. We assessed the anticoagulation and incidence of major cardiovascular events in hospitalized patients with AF and COVID-19.
View Article and Find Full Text PDFArticle Synopsis
- - Atrial fibrillation (AF) is frequently found in patients hospitalized with severe COVID-19, but there's limited guidance on how to manage their chronic anticoagulation therapy.
- - This study examined 305 AF patients with COVID-19 across 9 Spanish hospitals, comparing major bleeding, thrombotic events, and mortality against a control group of non-AF COVID-19 patients, revealing higher risks in the AF group.
- - The findings suggest that AF patients face increased risks for major bleeding and death during hospitalization, indicating that their anticoagulation therapy should be tailored based on individual risks.
Objective: To evaluate whether circulating cardiac troponin I (cTnI) levels are associated with worst outcomes in patients with atrial fibrillation (AF).
Methods: Consecutive patients visiting the emergency room (ER) with a new episode of a previously diagnosed AF or a new diagnosis of AF during ER admission between January 1st, 2010 and December 31st, 2015, were enrolled in the study (n = 2617). After applying exclusion criteria and eliminating repeated episodes, 2013 patients were finally included.